XSTO
VICO
Market cap246mUSD
Oct 09, Last price
9.00SEK
1D
3.45%
1Q
-29.47%
Jan 2017
-44.16%
IPO
70.61%
Name
Vicore Pharma Holding AB
Chart & performance
P/E
—
P/S
663.80
EPS
—
Div yield, %
—
Shrs. gr., 5y
-15.06%
Rev. gr., 5y
-11.73%
Revenues
4m
-96.51%
Net income
-477m
L+183.14%
CFO
-376m
L+127.79%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.
Key people
Carl-Johan Dalsgaard
Chief Executive Officer · since 2018
Hans Jeppsson
Chief Financial Officer · since 2017
Lena Lindblad
Operations Manager
Ulrike Muscha Steckelings
Chief Scientific Officer · since 2017
Nina Carlen
Head of Marketing and Communication
Bjorn Dahlof
Research & Development Consultant · since 2016
Johanna Grans
Regulatory Affairs Manager
Dan Isaksson
Senior R&D Chemist
Kicki Johansson
Head of Drug Development · since 2017
Anders Ljunggren
Research & Development Consultant
Klas Malmberg
Senior Medical Advisor · since 2016
Jacob Gunterberg
Director · since 2018
Maarten Kraan
Director · since 2018
Sara Malcus
Director · since 2018
Headquarters & legal address
Postbox 14
Göteborg, O 414 52
SE
Göteborg, O 414 52
SE
Address
Postbox 14
Goteborg, O 414 52
SE
Goteborg, O 414 52
SE
Previous name
Mintage Scientific AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||